MENXF yields 2000000.00% · PFE yields 6.13%● Live data
📍 MENXF pulled ahead of the other in Year 1
Combined, MENXF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MENXF + PFE for your $10,000?
Memex Inc. develops, commercializes, and manufactures a suite of products for its customers in the discrete manufacturing and aerospace sectors worldwide. The company primarily offers MERLIN Tempus, a software-driven industrial Internet of Things communications platform that provides manufacturing productivity metrics, including overall equipment effectiveness in real time. Its MERLIN Tempus measures and analyzes manufacturing and production performance, and provides its users with real-time insights on operational efficiency. The company also provides MERLIN Tempus Enterprise Edition for enhancing the value of time with enterprise resource planning connectivity and job scheduling; MERLIN financial Overall Equipment Effectiveness (FOEE), which enables factory organizations to link their shop floor performance to actual profit dollars; MERLIN Continuous Improvement (CI) Fast-track services, a nine-step implementation process; and MERLIN Operator Portal, a Windows based human machine interface (HMI) that provides operators with a live window into what information is being collected from the machines in real-time. In addition, the company provides MERLIN Enterprise Resource Planning connector, a bi-synchronous interface; MERLIN OPTime to assess, measure, identify, and optimize data-driven manufacturing; and SCANGun, a bar code scanner. Further, it offers IIoT hardware solutions, including MERLIN MTC-One that incorporate sensor-based process-driven data; MTConnect hardware adapter, which enables machine tool to communicate critical operational information using the MTConnect standard protocol; software adapters; and DNC memory upgrade products. Memex Inc. was founded in 1992 and is headquartered in Burlington, Canada.
Full MENXF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.